Universal Registration Document Including The Annual Financial Report

Overview

The report describes the company's 2020 consolidated revenue of €10,418,000 and the achievement of Tedopi's Step-1 primary endpoint, including a 46% 12-month survival rate. It also covers continued development of the CoVepiT COVID-19 vaccine, supported by €5.2 million of PSPC-COVID financing. The report additionally documents ongoing Phase 1 and Phase 2 clinical development across the company's immunotherapy portfolio.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2020
Period: Ends 31 December 2020
Publication date: 15 April 2021
Language: English
Pages
File size

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services